ST. PETERSBURG, Fla. — Kevin Cash had seen enough. Fifty-three pitches into Tuesday’s start against the Detroit Tigers, with the fastball sitting two miles per hour below its season average and the score already a humiliation, the Rays manager walked to the mound and made the call that had been building for two weeks. Steven Matz was done — not just for the afternoon, but for the foreseeable future as a starter.
Tampa Bay announced Saturday that the 35-year-old left-hander would move from the rotation to the bullpen, effective immediately. Matz had allowed 11 earned runs across his last two starts, surrendering a combined 13 hits and four home runs in fewer than five innings of work. His ERA, which had sat at 3.86 through seven appearances before an elbow injury interrupted his season, now stands at 5.48.
“It’s not by any stretch permanent,” Cash said Saturday, relayed by Marc Topkin of the Tampa Bay Times. “He will pitch out of the pen for the foreseeable future and then we will reassess.”
The reassurance landed with the awkward weight of a sentence no manager says about a pitcher who is pitching well. The numbers are the problem, but the numbers point back to something more specific: what happened to Matz’s arm in May and whether it has fully resolved.
Matz returned from the injured list May 20 after a stint with elbow inflammation. In the two months before he went on the IL, he had been a reliable back-end presence — a 3.86 ERA, consecutive quality starts, innings the Rays could budget around stronger arms at the front. The elbow problem arrived without warning, ending a stretch that had started to justify the two-year, $15 million contract Tampa Bay handed him in December.
Since coming back, something has shifted. Matz’s velocity readings are technically close to what they were before — 92 mph against the Tigers compared to his season average of 93.3 mph — but the granular data tells a harder story. According to MLB Trade Rumors, which cited advanced pitching metrics, his Stuff+ rating slipped from 98 before the IL stint to 91 after his return, and his swinging-strike rate has dropped by more than three percentage points across three post-IL outings. A pitcher can look like himself on the radar gun and still not be himself.
Against the Tigers on Tuesday, Matz gave up five runs and six hits in 1⅔ innings, two of them home runs, before Cash pulled him. In his previous start on May 27 against Baltimore, he lasted three innings and gave up six runs in an 11-2 loss. He told reporters afterward, “Got to try to work myself out of this rut and move forward” — a phrase that, in the context of a pitcher navigating post-injury mechanics, carries more uncertainty than it sounds.
Cash has not named a replacement in the rotation. That silence is its own statement: the Rays do not yet know what the fifth spot looks like, and they are not in a hurry to announce a permanent fix when a temporary one is still forming. According to the Tampa Bay Times, Mason Englert is expected to step into Matz’s rotation spot, possibly as a bulk reliever.
What complicates the picture is that Matz’s demotion is not a crisis for a struggling franchise. Tampa Bay entered Saturday’s play at 37-23, sitting first in the American League East, a game and a half ahead of the New York Yankees. The Rays have built their first-place standing without requiring Matz to be dominant. His value, should he find his footing out of the bullpen, is as a left-handed option against specific lineups — a role he actually played in 2025 with the St. Louis Cardinals and Boston Red Sox, where he posted a 2.08 ERA across 21 innings.
That bullpen effectiveness is not a new data point. It was always the argument against using Matz as a starter at all. Before Tampa Bay signed him, the expectation in some quarters was that he would pitch in relief, given his recent history and the team’s rotation depth. The Rays chose to put him in the rotation, and for seven starts it mostly worked. Then the elbow, and then this.
There is also a longer-range arithmetic problem here. Shane McClanahan and Drew Rasmussen, two of Tampa Bay’s rotation anchors, carry significant injury histories that will require careful management as the season progresses. With the trade deadline approaching and injury concerns reshaping rosters across the league, the Rays may look at a six-man rotation later in the summer as a way to limit innings on those arms. A healthier, shorter-outing Matz might fit back into that model.
Whether he gets there depends on what the elbow is actually doing. Inflammation is a word that covers a range of outcomes, from minor irritation that responds to rest, to structural wear that does not. Matz has not disclosed the severity of what he dealt with in May, and the Rays have not offered specifics. Cash framing this as a reassessment rather than a resolution suggests the organization is watching carefully rather than concluding anything.
Matz turns 36 in May 2027. He is in the second year of a deal that carries $7.5 million annually. For a 12-year veteran who has spent his career cycling between starting roles and bullpen assignments, the move Saturday is familiar territory. What is less familiar is navigating it on the wrong side of his mid-30s, with an elbow that raised a flag two months into the season and performance numbers that have not yet proven the flag was a false alarm.
His record this year stands at 4-3. Elbow concerns have rippled across MLB rotations this season, and Matz is the latest left-hander to find that returning from inflammation does not guarantee the same pitcher returns to the mound. Cash was careful with his language on Saturday. He did not say the rotation door is closed. He said they will reassess. In baseball, that can mean many things. It does not always mean the same pitcher comes back.
For now, Matz heads to the bullpen of a first-place team, with a start scheduled for Monday against Boston that will no longer happen. Aaron Judge’s injury has opened a gap in the AL East that Tampa Bay cannot afford to squander. The Rays will manage his absence in the rotation without having said, yet, whose job it is to fill it.
